No Data
No Data
Exact Sciences' Stock Resilience and Legal Outlook Drive Buy Rating
Exact Sciences Launches the Oncodetect MRD Test
Exact Sciences Launch of Oncodetect A New Test Designed To Detect Molecular Residual Disease (MRD) Across Multiple Solid Tumors
Exact Sciences Launches the Oncodetect Molecular Residual Disease Test
TD Cowen Maintains Exact Sciences(EXAS.US) With Buy Rating, Cuts Target Price to $75
Express News | Exact Sciences Corp : TD Cowen Cuts Target Price to $75 From $86